Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,301 to 1,320 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure-Activity Relationship Studies. | J Med Chem | 2022 | 35119851 | PubTator, text mining | PubMed |
| Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers. | World J Gastrointest Oncol | 2022 | 35116104 | PubTator, text mining | PubMed |
| Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry. | Hemasphere | 2022 | 35106452 | PubTator, text mining | PubMed |
| Genomic characterization of functional high-risk multiple myeloma patients. | Blood Cancer J | 2022 | 35102139 | PubTator, text mining | PubMed |
| Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs. | J Biol Chem | 2022 | 35101445 | PubTator, text mining | PubMed |
| Targeting the "undruggable" RAS with biologics. | Adv Cancer Res | 2022 | 35101232 | PubTator, text mining | PubMed |
| CDK9 inhibitors in multiple myeloma: a review of progress and perspectives. | Med Oncol | 2022 | 35092513 | PubTator, text mining | PubMed |
| Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. | Leukemia | 2022 | 35082402 | PubTator, text mining | PubMed |
| 3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O'PROTAC. | Chem Commun (Camb) | 2022 | 35080528 | PubTator, text mining | PubMed |
| A natural product targets BRD4 to inhibit phase separation and gene transcription. | iScience | 2022 | 35072011 | PubTator, text mining | PubMed |
| Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention. | Pharmaceutics | 2022 | 35057104 | PubTator, text mining | PubMed |
| Targeted Therapy in Leukaemia, Lymphoma and Myeloma. | J Pers Med | 2022 | 35055389 | PubTator, text mining | PubMed |
| Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities. | Haematologica | 2022 | 35045690 | PubTator, text mining | PubMed |
| The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases. | J Mol Biol | 2022 | 35045330 | PubTator, text mining | PubMed |
| PROTAC targeted protein degraders: the past is prologue. | Nat Rev Drug Discov | 2022 | 35042991 | PubTator, text mining | PubMed |
| Targeted protein degradation: Emerging concepts and protein state-specific targeting principles. | Curr Opin Chem Biol | 2022 | 35042023 | PubTator, text mining | PubMed |
| Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. | Heliyon | 2022 | 35036599 | PubTator, text mining | PubMed |
| The Sec61 translocon is a therapeutic vulnerability in multiple myeloma. | EMBO Mol Med | 2022 | 35014767 | PubTator, text mining | PubMed |
| A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues. | Nat Commun | 2022 | 35013300 | PubTator, text mining | PubMed |
| Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications. | J Am Chem Soc | 2022 | 34994556 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=66